Replies to post #171772 on Vivos Inc (RDGL)

[DomerJon]

Only one here with no credibility and makes no sense is you. Go away. check back in a year. run along now.

[mc73]

Agree with your statement. Earlier I was too busy with work and shouldn't have posted until I had time to read and digest the information properly.

From today's Tweet the statement "You may have noticed we are promoting our IsoPet division more than ever these days and this is why..." and first paragraph in the meme (for lack of a better term) "Why our IsoPet division is so important...'increases the likelihood of IsoPet becoming a practical solution in the treatment of animal cancer.'" demonstrates that the work is clearly for the IsoPet division which costs more money than it generates and Dr. K hasn't given shareholders any evidence of a plan to make the IsoPet Division profitable. This concerns me and SHOULD concern all shareholders.

The second paragraph of the meme "Additionally, the data obtained at the University of Missouri will support the pre-clinical investigations required by the FDA to provide evidence that RadioGel can be safe and effective for treating various human cancers." confirms that the data from study at U of Missouri is being used towards RadioGel IDE application. What is confusing at best and deliberately misleading at worst is why he inserted this paragraph. The study at U of Missouri was done 2+ years ago and has nothing to do with why they are currently promoting IsoPet division so hard. VERY misleading.

I suppose this is good news if you like a division of a company that, to date, has cost more than the revenue it generates and there is no roadmap to increased revenue, let alone profitability AND you can block out/ignore the misleading U of Missouri paragraph. Personally, I am not a fan of the CEO bragging about a division that looses money. Furthermore, I really hate the fact that he threw (old) 2 year old animal study data for RadioGel onto the Tweet when the focus is clearly on IsoPet work ongoing today. It makes no sense as he could have left off the 2nd paragraph and the Tweet would have been more focused on what is relevant and current - lots of IsoPet work being done by company so it eventually becomes routine care in the treatment of animal cancer.

It is what it is...thank God the FDA is walking us thru the IDE application process as it is all that really matters.